SCHEMBL620853

SCHEMBL620853

NCc1cc(F)ccc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
MPO P05164 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.41
NPC1 O15118 1/20 0.40
HTR2A P28223 1/20 0.38
OXTR P30559 1/20 0.38
AVPR1A P37288 1/20 0.38
BACE1 P56817 1/20 0.37
MEN1 O00255 2/20 0.37
RAD52 P43351 2/20 0.37
RECQL P46063 2/20 0.37
KMT2A Q03164 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
GAPDH P04406 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12215820 0.84 CA3 (0.52) CA3CA6CA5ACA9CA14
SCHEMBL29429208 0.84 CA3 (0.52) CA3CA6CA5ACA9CA14
SCHEMBL27587521 0.83 RECQL (0.59) CA3CA6CA5ACA9CA14
Hydrochloric Acid SCHEMBL2531698 0.82 CA3 (0.50) CA3CA6CA5ACA9CA14
SCHEMBL1616373 0.81 HIF1A (0.54) CA3CA6CA5ACA9CA14
Hydrochloric Acid SCHEMBL21815105 0.81 RECQL (0.61) CA3CA6CA5ACA9CA14
SCHEMBL24299331 0.79 MPO (0.50) CA3CA6CA5ACA9CA14
SCHEMBL1906156 0.79 KLF10 (0.50) CA3CA6CA5ACA9CA14
SCHEMBL1398042 0.78 MPO (0.48) MPOLOXL2HTR2AKMT2AIDO1
SCHEMBL364672 0.77 ESR1 (0.53) CA3CA6CA5ACA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3697860-A2 SURFACE TREATMENT Interphase Materials Inc. (US) 2020-08-26 EP claimed
US-20200231842-A1 Surface Treatment INTERPHASE MAT INC (US) 2020-07-23 US claimed
WO-2019164546-A2 SURFACE TREATMENT INTERPHASE MATERIALS INC. (US) 2019-08-29 WO claimed
WO-2010139288-A1 5,7-DISUBSTITUTED 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES FOR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS C3 BIO GMBH (DE) 2010-12-09 WO claimed
US-20260028352-A1 MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) 2026-01-29 US disclosed
EP-4585598-A1 MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) 2025-07-16 EP disclosed
US-20250075101-A1 SURFACE TREATMENT Interphase Materials, Inc (US) 2025-03-06 US disclosed
US-12146071-B2 Surface treatment INTERPHASE MATERIALS INC. (US) 2024-11-19 US disclosed
CN-117624166-A Triazole derivative and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-03-01 CN disclosed
CN-117586277-A Macrocyclic triazole derivative and preparation method and application thereof 苏州朗睿生物医药有限公司 2024-02-23 CN disclosed
WO-2024032390-A1 MACROCYCLIC TRIAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州朗睿生物医药有限公司 2024-02-15 WO disclosed
CN-116640119-A Preparation method of pomalidomide derivative 成都毓欣科技有限公司 2023-08-25 CN disclosed
WO-2011134444-A2 SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-03 WO disclosed
WO-2010139288-A1 5,7-DISUBSTITUTED 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES FOR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS C3 BIO GMBH (DE) 2010-12-09 WO disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
CN-101316841-A Arylmethylene urea derivative and use thereof TORAY INDUSTRIES (JP) 2008-12-03 CN disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF UROD, UTS2R, SLC14A1 CA3 4865/4885CA6 3528/4885CA5A 3875/4885
US-20260028352-A1 MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF WEE2, WEE1, ROR1 CA3 3990/4885CA6 3629/4885CA5A 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.